As 2025 ends, delve into some biotech feel-good stories where the right treatment meets the right patient, almost feeling ...

A strict new vaccine approval process in the U.S. could dramatically slow things down for biopharma and the public, experts ...

Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

BIO-Europe Startup Spotlight returns to Lisbon in March 2026, showcasing Europe’s top early-stage biotech pitches to industry ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...

A company that hardly needs an introduction is Eli Lilly, but what has it been up to lately, and what’s its pipeline strategy? Over the past year, Lilly has mixed headline-grabbing science with ...

The news that the organization led a $35 million funding round for London-based Portal Biotech came about two weeks ago. Portal Biotech’s focus is on the field of proteomics, which is the study of ...

Antibody therapies constitute a vast global market: currently valued at over $250 billion, the market for antibodies is expected to exceed $850 billion worldwide by 2032. Driving forces behind this ...

Migraines are not simply a bad headache; they are a neurological disorder that can significantly impact daily life. Often characterized by throbbing pain on one side of the head, they can be moderate ...

We’re nearly halfway through 2025, and like clockwork, the American Society of Clinical Oncology (ASCO) annual summit took place from the 30th of May to the 3rd of June in Chicago this year. With ...